Monotherapy with gilteritinib and quizartinib has shown superior response rates in FLT3 mutant relapsed/refractory AML when compared to standard salvage chemotherapy as demonstrated by the phase 3 ADMIRAL and QuANTUM-R trials, respectively [21, 22]. Here, FLT3 is linked to acute myeloid leukemia.